Trabecular bone score (TBS) may be an effective, indirect measurement of bone quality in patients with type 2 diabetes (T2D), according to research presented at the 2017 World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases, which took place March 23-26, 2017, in Florence, Italy.

Researchers from Brussels, Belgium, conducted a cross-sectional analysis of patients with T2D to determine how a diabetes diagnosis has an impact on patients’ bone mineral density (BMD) and influences future fracture risk.

Participants were pulled from the FRISBEE study — an ongoing, prospective epidemiological study of a population-based cohort located in Brussels, Belgium; 260 out of 3560 postmenopausal women were included in the researchers’ analysis.

 

All participants had baseline dual-energy X-ray absorptiometry (DXA) scans. Two groups were created: participants with T2D (n=65) and participants without T2D (n=195) serving as controls. TBS was calculated for all participants based on lumbar spine DXA examination.

Mean age was similar in both groups (69.9±5.8 years in the T2D group and 69.8±5.6 in the control groups); fracture risk scores (FRAX) were also similar (9.5±6.7 and 9.9±6.7, respectively).

While the investigators found no significant difference in mean T score values, mean TBS was significantly lower in the T2D group vs the control group (1.185±0.172; 95% CI, 1.14-1.22 vs 1.267±0.132; 95% CI, 1.24-1.28; P =.005).

“Despite similar DXA values, we found a lower TBS score in diabetic compared with nondiabetic subjects,” the researchers concluded.

 “These results are in line with the current view that [type 2 diabetes] induces microarchitectural deteriorations of bone tissue. Moreover, our data suggest that TBS may be a useful tool in the assessment of bone quality in T2DM.”

Related Articles

Reference

Baleanu F, Bergmann P, Hambye AS, et al. Assessment of bone quality with trabecular bone score (TBS) in type 2 diabetes mellitus (T2DM). Abstract P832. Presented at: 2017 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. March 23-26, 2017; Florence, Italy.